Ucb Pharma Gmbh

Cécile Pegurier

Ali El-Tayeb

Christa E Mueller

Joerg Hockemeyer

Marie Ledecq

Laurent Provins

Michael Louis Robert Deligny

Anaïs Barré

Sabrina Gollos

Lukas Schwach

Vigneshwaran Namasivayam

Sanjay Bhattarai

Nader M Boshta

Joël Mercier

Mario Funke

Daniel Von Laufenberg

Silvia Lovera

Yong-Qiang Zhang

Nader Boshta

Mahmoud Rashed

Alvaro Cardenas

Emre M Isin

Larurent Provins

Disclosed are N-(phenyl)-1H-indole-3-sulfonanmide and N-(phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related compounds (e.g. the N-pyridin-2-yl and the N-pyridin-3-yl analogues thereof). The present compounds have GPR17 modulating properties which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating disorders such as multiple sclerosis.

N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides

The present application relates to alkoxy-substituted pyridinyl indolsulfonamides. The compounds are negative GPR17 modulators and have utility in the treatment of various GPR17 associated disorders.

Substituted alkoxypyridinyl indolsulfonamides

The present invention relates to pyridinyl and pyrazinyl-(aza)indolsulfonamides having GPR17 modulator activity. The compounds have utility in the treatment of a variety of GPR17-associated disorders.

Pyridinyl and pyrazinyl-(asa)indolsulfonamides

Growing community of inventors

Uccle, Belgium

Cécile Pegurier